Three Healthcare IPO Filers to Watch Amid Pre-Market Volatility

During the pre-market trading session on Wednesday, the U.S. healthcare sector did not rise as a whole, showing a divergent trend. The performance of the six major U.S. pharmaceutical giants was divided into three categories:Johnson & Johnson+3.4%,AbbVieUp 2.1%,Merck & Co.+3.6%Eli LillyStock price remains flat,Pfizer-1.4%, Bristol MyersBristol-Myers Squibb+1.5%.

Key data for the core bid are as follows:

Amid the current sector divergence, a barbell strategy is recommended: allocate to AbbVie, which features resonant growth and profitability with solid fundamentals, and Johnson & Johnson, which offers reasonable valuation and stable dividends. With a combined market capitalization exceeding $990 billion, these two companies enable diversified exposure within the sector. Avoid stocks whose price trends are disconnected from fundamentals: Moderna’s rise lacks fundamental support and represents pure momentum trading, while Pfizer’s high dividend corresponds to deteriorating fundamentals. The recent price movements of both stocks are not reliable indicators; core investment signals should be based on fundamental-driven metrics.

Translation content provided by third-party software.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on publicly available information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; please refer to actual announcements for authoritative information. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express